# Selank References: The Studies Cited on This Site

> Selank references: the full, cited list of peer-reviewed studies behind every claim on this site, with PubMed links and DOIs where available.

The peer-reviewed studies behind every cited claim on this site, numbered to match the [N] markers throughout.

## About these references

Every numbered marker on this site maps to one of the studies below. The Selank evidence base is concentrated in Russian research groups and Russian-language journals (English abstracts available), which is the single biggest caveat to keep in mind when reading any Selank claim. Where a DOI exists it is listed; every entry links to its PubMed record.

## References

[1] Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein Pept Lett. 2018;25(10):914-923. https://pubmed.ncbi.nlm.nih.gov/30255741/
[2] Zozulya AA, Kost NV, Sokolov OYu, et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bull Exp Biol Med. 2001;131(4):315-317. https://pubmed.ncbi.nlm.nih.gov/11550013/
[3] Inozemtseva LS, Karpenko EA, Dolotov OV, et al. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Dokl Biol Sci. 2008;421:241-243. https://pubmed.ncbi.nlm.nih.gov/18841804/
[4] Volkova A, Shadrina M, Kolomin T, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Front Pharmacol. 2016;7:31. https://pubmed.ncbi.nlm.nih.gov/26924987/
[5] Uchakina ON, Uchakin PN, Miasoedov NF, et al. Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(5):71-75. https://pubmed.ncbi.nlm.nih.gov/18577961/
[6] Zozulia AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic medication (selank) in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. https://pubmed.ncbi.nlm.nih.gov/18454096/
[7] Kasian A, Kolomin T, Andreeva L, et al. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behav Neurol. 2017;2017:5091027. https://pubmed.ncbi.nlm.nih.gov/28280289/
[8] Kolik LG, Nadorova AV, Kozlovskaya MM, et al. Efficacy of peptide anxiolytic selank during modeling of withdrawal syndrome in rats with stable alcoholic motivation. Bull Exp Biol Med. 2014;157(1):52-55. https://pubmed.ncbi.nlm.nih.gov/24913576/
[9] Kolik LG, Nadorova AV, Seredenin SB, et al. Selank Inhibits Ethanol-Induced Hyperlocomotion and Manifestation of Behavioral Sensitization in DBA/2 Mice. Bull Exp Biol Med. 2016;162(1):56-59. https://pubmed.ncbi.nlm.nih.gov/27878720/
[10] Kolik LG, Nadorova AV, Antipova TA, et al. Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment in Rats. Bull Exp Biol Med. 2019;167(5):641-644. https://pubmed.ncbi.nlm.nih.gov/31625062/
[11] Konstantinopolsky MA, Chernyakova IV, Kolik LG, et al. Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal Syndrome. Bull Exp Biol Med. 2022;173(6):730-733. https://pubmed.ncbi.nlm.nih.gov/36322304/
[12] Mukhina AY, Mishina ES, Bobyntsev II, et al. Morphological Changes in the Large Intestine of Rats Subjected to Chronic Restraint Stress and Selank Administration. Bull Exp Biol Med. 2020;169(2):281-285. https://pubmed.ncbi.nlm.nih.gov/32651826/
[13] Sarkisova KIu, Kozlovskii II, Kozlovskaia MM, et al. Effects of heptapeptide selank on genetically-based and situation-provoked anxiety in rats. Zh Vyssh Nerv Deiat Im I P Pavlova. 2008;58(2):226-237. https://pubmed.ncbi.nlm.nih.gov/18661785/
[14] Kolomin TA, Agapova TIu, Agniullin IaV, et al. Transcriptome alteration in the hippocampus under the treatment with the tuftsin analog Selank. Zh Vyssh Nerv Deiat Im I P Pavlova. 2013;63(3):365-374. https://pubmed.ncbi.nlm.nih.gov/24450168/
[15] Vasil'eva EV, Kondrakhin EA, Salimov RM, et al. Comparison of Pharmacological Effects of Heptapeptide Selank After Intranasal and Intraperitoneal Administration. Eksp Klin Farmakol. 2016;79(9):3-11. https://pubmed.ncbi.nlm.nih.gov/29787664/
[16] Medvedev VE, Tereshchenko ON, Kost NV, et al. Optimization of the treatment of anxiety disorders with selank. Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(6):33-40. https://pubmed.ncbi.nlm.nih.gov/26356395/
[17] Fomenko EV, Bobyntsev II, Kryukov AA, et al. Effect of Selank on Functional State of Rat Hepatocytes under Conditions of Immobilization Stress. Bull Exp Biol Med. 2017;163(4):415-418. https://pubmed.ncbi.nlm.nih.gov/28853100/
[18] Narkevich VB, Kudrin VS, Klodt PM, et al. Effects of heptapeptide selank on the content of monoamines and their metabolites in the brain of BALB/c and C57Bl/6 mice. Eksp Klin Farmakol. 2008;71(5):8-12. https://pubmed.ncbi.nlm.nih.gov/19093364/
[19] Leonidovna YA, Aleksandrovna SM, Aleksandrovna TA, et al. The Influence of Selank on the Level of Cytokines Under the Conditions of Stressogenic Effect. Curr Rev Clin Exp Pharmacol. 2021;16(2):162-167. https://pubmed.ncbi.nlm.nih.gov/32621722/
[20] Ershov FI, Uchakin PN, Uchakina ON, et al. Antiviral activity of immunomodulator Selank in experimental influenza infection. Vopr Virusol. 2009;54(5):19-24. https://pubmed.ncbi.nlm.nih.gov/19882898/

---

A friendly, honestly-cited digest of the Selank research — bright on the page, careful with the evidence.